Month: September 2026

New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to RAS(ON) & Pan-RAS Therapies

MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of its lead candidate PRP against recently reported clinical datasets from leading RAS-targeted programs, including Revolution Medicines’ daraxonrasib (RASONQUE™; RMC-6236) and Erasca’s pan-RAS molecular glue ERAS-0015.

The analysis is intended to clarify two distinct layers of tumor biology. RAS inhibitors block oncogenic RAS signaling and have produced practice-changing clinical results in RAS-mutant pancreatic ductal adenocarcinoma (PDAC) and encouraging activity in RAS-mutant non-small cell lung cancer (NSCLC). PRP, a proprietary fixed-ratio combination of the pancreatic proenzymes, trypsinogen and chymotrypsinogen, does not inhibit RAS. Instead, it promotes differentiation of malignant cells toward a more normal phenotype, reverses epithelial-mesenchymal transition (EMT), depletes cancer stem cells (CSCs), and remodels the fibrotic tumor microenvironment (TME).

Propanc believes these mechanisms address residual drivers of resistance, dormancy, and metastasis that can persist after RAS pathway blockade – creating a scientific rationale for combination or sequential use with RAS inhibitors.

A Landmark Moment for RAS-Targeted Therapy

RAS mutations drive approximately 90% of PDAC and roughly 30% of NSCLC. For decades the target was considered undruggable. That landscape has shifted rapidly.

Revolution Medicines – daraxonrasib: In the randomized Phase 3 RASolute 302 trial in previously treated metastatic PDAC, oral once-daily daraxonrasib produced median overall survival (OS) of 13.2 months versus 6.6–6.7 months with investigator’s-choice chemotherapy (hazard ratio 0.40; p < 0.0001), median progression-free survival (PFS) of 7.3 months versus 3.5 months, and an objective response rate (ORR) of approximately 33% versus 12%. The U.S. Food and Drug Administration approved daraxonrasib in August 2026 for pretreated metastatic pancreatic adenocarcinoma. In previously treated RAS-mutant NSCLC, a Phase 1/2 study published in The New England Journal of Medicine reported ORRs of 31–37% across evaluated dose bands; in a docetaxel-naïve subgroup treated at 160–220 mg, confirmed ORR was 42%, disease-control rate 89%, median PFS 8.3 months, and median OS 16.0 months.

Erasca – ERAS-0015: Preliminary Phase 1 monotherapy data from the U.S. AURORAS-1 and China JYP0015M101 trials showed unconfirmed overall response rates (uORR) of 62% in second-line or later KRAS G12X NSCLC at pharmacologically active doses of 16–32 mg once daily, and 75% in the post-checkpoint-inhibitor / platinum 2/3L NSCLC subset. In second-line KRAS G12X PDAC, uORR was 40% at 16–32 mg and 42% at recommended expansion doses of 24–32 mg; a July 2026 update reported a 57% uORR at 8 weeks at the 32 mg recommended expansion dose in 2L+ KRAS G12X PDAC. The program has been generally well tolerated to date, with mostly low-grade treatment-related adverse events and no dose-limiting toxicities reported at disclosed cutoffs. Erasca has described ERAS-0015 as a potentially best-in-class pan-RAS molecular glue and has outlined registration-enabling plans in pancreatic and lung cancers.

These datasets validate RAS as a therapeutically tractable node. They also leave an open clinical question: how to convert high response rates and doubled survival into durable, metastasis-free outcomes when residual mesenchymal and stem-like cells remain.

PRP Preclinical Profile in Advanced PDAC

In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, three-times-weekly intravenous PRP achieved:

• Greater than 90%, mean, tumor-growth inhibition versus vehicle controls (p < 0.001).
• Marked reduction in metastatic burden in liver and peritoneum.
• Significant TME remodeling, including decreased cancer-associated fibroblast (CAF) activity, reduced fibrosis, and suppression of EMT markers.
• Re-sensitization of chemo-resistant PDAC cells to gemcitabine/nab-paclitaxel, supporting lower chemotherapy doses with improved efficacy.
• Median overall survival extension of more than 2.5-fold versus controls.

These findings are built on previously reported >85% tumor-growth inhibition, peer-reviewed work on PRP’s effects on PDAC fibroblasts and CSCs, and limited prior compassionate-use experience with related proenzyme formulations that showed signals of prolonged survival and a favorable safety profile with no severe treatment-related adverse events. PRP holds FDA Orphan Drug Designation for pancreatic cancer and is not restricted to a specific RAS genotype.

Important context: PRP efficacy cited here is preclinical. Daraxonrasib and ERAS-0015 data are from human clinical trials. Cross-modality numerical comparisons are directional only and are not head-to-head results.

Comparative Snapshot

Attribute	PRP (PPCB)	Daraxonrasib	ERAS-0015
Modality	IV proenzyme combo (trypsinogen + chymotrypsinogen, 1:6)	Oral RAS(ON) multi-selective inhibitor	Oral pan-RAS molecular glue
Primary node	Differentiation / EMT reversal / CSCs / TME	Oncogenic RAS(ON) signaling	Pan-RAS (KRAS G12X and related)
Evidence stage	Preclinical PDAC + limited compassionate use; Phase 1b planned Feb 2027	Phase 3 PDAC (approved Aug 2026); Phase 1/2 NSCLC in NEJM	Phase 1 dose-escalation / expansion; registration path outlined
PDAC activity	>90% TGI; >2.5× median OS in models; metastasis and fibrosis reduced	Ph3 2L: mOS 13.2 vs 6.6–6.7 mo; mPFS 7.3 vs 3.5 mo; ORR ~33% vs ~12%	Ph1 2L KRAS G12X: uORR 40–42%; 57% uORR8wk at 32 mg RDE (2L+)
NSCLC activity	Not a primary disclosed indication to date	Ph1/2 RAS-mutant: ORR 31–37%; docetaxel-naïve subset ORR 42%, mOS 16 mo	Ph1 2L+ KRAS G12X: uORR 62%; post-ICI/platinum 2/3L uORR 75%
Genotype limit	Not RAS-mutation restricted	RAS-mutant tumors (multi-selective, non-G12C-only)	RAS / KRAS G12X enriched populations
Resistance biology addressed	EMT, CSCs, CAFs, fibrosis, metastasis, chemo-re-sensitization	Oncogene-addicted proliferation; adaptive MAPK reactivation remains a known class issue	RAS output; combinations (e.g., anti-EGFR) being explored

^{Sources: Company disclosures & peer-reviewed or conference reports for September 2026. Figures are not from a single comparative trial.}

How Reversal of EMT Occurs — and Why It Matters After RAS Blockade

EMT is a developmental program co-opted by carcinomas. When it is activated, epithelial tumor cells lose polarity and adhesion, acquire a mesenchymal, invasive, and stem-like state, and become more resistant to apoptosis, chemotherapy, and targeted agents. In PDAC, EMT is tightly coupled to TGF-β signaling, a dense desmoplastic stroma, CAF activation, and a CSC reservoir that seeds metastasis and late relapse.

Oncogenic RAS feeds this program. KRAS signaling promotes MAPK- and PI3K-dependent transcriptional networks that stabilize EMT transcription factors, loosen cell–cell junctions, and maintain stemness. RAS inhibitors can collapse that upstream drive and produce rapid tumor shrinkage. They do not, by themselves, reliably extinguish cells that have already completed EMT or that reside in a fibrotic niche that limits drug penetration and immune access. Those residual populations are a leading hypothesized source of acquired resistance to RAS-targeted drugs.

PRP acts at a different biological layer:

• Proenzyme activation and PAR signaling: After intravenous administration, trypsinogen and chymotrypsinogen are activated and engage proteinase-activated receptors (PAR-1 and PAR-2), which are frequently overexpressed on tumor cells. This cascade is associated with reduced TGF-β pathway output — a master inducer of EMT in late-stage cancer.
• Restoration of an epithelial phenotype: Peer-reviewed studies show PRP increases epithelial adhesion proteins such as E-cadherin and β-catenin and decreases EMT transcription factors. Cells become less motile, more adherent, and more differentiated — the operational definition of EMT reversal (sometimes described as mesenchymal-to-epithelial transition, or MET).
• Depletion of cancer stem cells: In pancreatic CSC models, PRP reduced ALDH-high cells and surface markers CD44, CD326, and CXCR4; suppressed primary and secondary sphere formation; down-regulated CSC and metastasis gene programs; and impaired tumor engraftment in vivo.
• TME and fibroblast remodeling: PRP decreased CAF activity and fibrosis in PDAC models. A less desmoplastic stroma can improve drug delivery and reduce TGF-β-driven conversion of non-stem tumor cells into CSCs — a problem that pathway inhibitors alone do not solve.
• Chemo- and pathway-sensitization: By pushing cells out of a mesenchymal, drug-tolerant state, PRP resensitized chemo-resistant PDAC cells to gemcitabine/nab-paclitaxel at lower doses. The same logic applies to RAS inhibitors: a smaller mesenchymal reservoir should theoretically reduce the probability of adaptive escape.

In short, RAS inhibitors turn the oncogenic engine off. PRP is designed to convert the remaining cells back toward a less dangerous epithelial identity and to dismantle the niche that protects them. The two approaches are biologically orthogonal.

Strategic Implication for RAS Inhibitor Developers

For companies such as Revolution Medicines and Erasca, durability — not only response rate — will define long-term competitive position as multiple RAS agents enter the same PDAC and NSCLC populations. Three practical implications follow from the EMT-reversal thesis:

• Combination potential: A RAS inhibitor plus an EMT-reversing, CSC-targeting agent could pair rapid cytoreduction with suppression of the cells most likely to seed resistance. PRP’s non-cytotoxic differentiation mechanism and historically benign compassionate-use safety profile make it a candidate for add-on or maintenance designs that RAS companies are already exploring with chemotherapy, anti-EGFR antibodies, and RAS-doublet regimens (for example, zoldonrasib plus daraxonrasib).
• Post-progression and maintenance use: When tumors adapt to RAS blockade, mesenchymal drift and fibrotic remodeling are common escape routes. An agent that reverses EMT and reduces CAFs could be sequenced after RAS-inhibitor response to lock in epithelial differentiation and limit metastatic outgrowth.
• Broader eligible population: PRP is not genotype restricted. In mixed RAS-mutant / RAS-wild-type settings, or in tumors that lose RAS dependence after therapy, a differentiation backbone could extend benefit beyond the label of any single RAS agent.

Propanc is not announcing a partnership with Revolution Medicines or Erasca. The Company is putting the mechanistic case on record as it advances PRP into first-in-human development and as the RAS field looks beyond first-generation survival gains.

Clinical Path

Propanc plans to initiate a multicenter, open-label Phase 1b first-in-human study of PRP in February 2027 in up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at sites in Australia. The two-part design will use Bayesian optimal interval dose escalation with backfill, followed by tumor-specific expansion. PRP is planned as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle. GMP manufacture, pharmacokinetics assay validation, and ethics submissions are advancing in parallel.

“RAS inhibitors have rewritten what is possible in pancreatic and RAS-mutant lung cancer. That is a genuine inflection point for patients,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Our thesis is that turning RAS off is necessary but may not be sufficient. The cells that survive RAS blockade are often the mesenchymal, stem-like cells that PRP differentiate and disarm. If that biology holds in the clinic, PRP could help RAS-focused companies convert high response rates into longer, cleaner remissions.”

“EMT is the program that lets a carcinoma leave home, hide, and return,” said Dr. Ralf Brandt, Propanc’s Research & Development Director. “PRP does not compete with daraxonrasib or ERAS-0015 at the GTPase. It reverses the downstream identity change those tumors used to resist almost every class of drug. That is why we see suppression of EMT markers, loss of CSC phenotypes, less fibrosis, fewer metastases, and more than a two-and-a-half-fold survival extension in PDAC models. Those are the exact liabilities a RAS inhibitor leaves on the table.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780

info@propanc.com

Investor Contact:

irteam@propanc.com

Reciprocal partnership pairs the two platforms to accelerate growth on both sides, building on Amaze’s strategic investment in C2

COSTA MESA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze”), a company focused on creator-powered commerce, today announced it is deepening its relationship with C2 Live Inc. (“C2”) (C2Live.co), a creator-first live social platform and subsidiary of C2 Capital Group, Inc., through a new mutual referral partnership. Building on the company’s previously announced strategic investment, the partnership puts Amaze’s and C2’s ecosystems to work for one another — turning a capital relationship into an active, revenue-generating collaboration across both platforms.

Mutual Agency Partnership

The partnership is designed to create new revenue opportunities for creators and audiences across both platforms, including expanded engagement and monetization through cross-promotional initiatives spanning each company’s creator, brand and audience ecosystems. Amaze has built more than 14 million creator storefronts over the course of its history, while C2 has approximately 1.5 million registered users.

Under the arrangement, each company promotes the other across its email lists and product using dedicated affiliate links and codes. Each party earns a 10% fee on revenue from its user and creator base.

Together, the platforms are positioned to capture share of a global creator economy that Goldman Sachs projects will reach approximately $480 billion by 2027.

Management Commentary

“This partnership is about giving creators more ways to turn real-time engagement into income,” said Joel Krutz, Interim Chief Executive Officer of Amaze. “By connecting our infrastructure and tools to C2’s live social platform we’re opening new paths for monetization across both ecosystems.”

“We’re excited to deepen the partnership with Amaze, this gives our users new ways to grow their audiences, and to generate new revenue,” said Lamont Wilcott, Chief Executive Officer of C2.

Amaze intends to provide further information regarding the transaction as appropriate. Investors are encouraged to review Amaze’s filings with the Securities and Exchange Commission at www.sec.gov.

For investor information, please contact IR@amaze.co.
For press inquiries, please contact PR@amaze.co.

About Amaze

Amaze Holdings, Inc. is an end-to-end, creator-powered commerce platform offering tools for brand development, product creation, advanced e-commerce, audience growth and scalable managed services. By helping people turn what they know, create and share into sustainable income, Amaze enables creators to build deeper audience relationships and more flexible paths to a better life. Discover more at www.amaze.co.

About C2

C2 is a creator-first live streaming platform that adds a social layer to live video by connecting creators and audiences through real-time interaction, gamification and community. Its engagement-driven model enables creators to monetize direct audience participation through virtual goods and interactive experiences. With a growing presence across North America and Asia, C2 is developing a broader suite of tools and services designed to support creators in building, engaging and monetizing their audiences. C2 is operated by C2 Live Inc., a subsidiary of C2 Capital Group, Inc. For more information, visit C2Live.co.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). These statements relate to the referral partnership with C2, the strategic investment, and the resulting future business relationship. These statements can be identified by words such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and are based on our current expectations and views concerning future events and developments and their potential effects on us. Some or all of these forward-looking statements may not occur.

Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that the referral partnership does not produce the anticipated creator acquisition or referral revenue; (ii) the incurrence of unexpected costs, liabilities or delays relating to the partnership or the investment; (iii) the occurrence of a material adverse change in the business, assets, or financial condition of C2 Capital; (iv) the risk that the anticipated benefits of the partnership or the investment are not realized on the anticipated timeline, or at all; and (v) risks include the Risk Factors contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025.

Source: Amaze Holdings, Inc.

Experienced medical device quality and regulatory leader brings 13 years of experience supporting quality systems, regulatory compliance, audits and product development

MINNEAPOLIS, Sept. 16, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Brian Johnson as Director of Quality and Regulatory Affairs. Johnson brings 13 years of medical device quality and regulatory experience, with a proven track record leading quality systems, regulatory activities, audits and product development initiatives. His appointment strengthens Nuwellis’ quality and regulatory capabilities as the Company continues to invest in the expertise needed to advance product development, commercialization and initiatives across the cardiorenal continuum.

“Brian’s experience leading quality and regulatory functions within medical device organizations makes him an important addition to our team,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “As we continue to advance our product portfolio and execute on multiple strategic initiatives, Brian brings the leadership and technical expertise needed to enhance our quality and regulatory capabilities while supporting our focus on innovation and execution.”

Prior to joining Nuwellis, Johnson served as Senior Quality Manager at Baxter/Vantive, providing quality oversight for two research and development facilities supporting 257 engineering and management employees. Previously, he held quality leadership roles at ATL Medical, where he led research and development and manufacturing quality activities and helped reduce monthly customer complaints by 80%. Johnson holds a Master of Science in Regulatory Affairs and Services from St. Cloud State University and a Bachelor of Science in Manufacturing Engineering Technology from Brigham Young University.

In his new role, Johnson will lead Nuwellis’ quality management and regulatory activities, including quality systems, audits, supplier and contract manufacturer oversight, and regulatory compliance. He will work cross-functionally with product development, operations and commercial teams to support product quality and the continued advancement of Nuwellis’ technology portfolio. Johnson will also support continuous improvement initiatives as the Company advances multiple product development programs.

The appointment of Johnson builds on Nuwellis’ continued investment in the expertise needed to support product development and commercialization. The Company has also recently added expertise in medical affairs and engineering, further strengthening its capabilities across clinical development, product innovation, quality and regulatory execution as Nuwellis advances multiple strategic initiatives.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ strategy includes expanding its portfolio through internally developed technologies and strategic commercial partnerships that broaden its presence across acute and chronic critical care. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

LAS VEGAS, Sept. 16, 2026 (GLOBE NEWSWIRE) — Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce the completion of its USD $5.5 million acquisition of the La Vencedora mining concession, a high-grade underground gold and silver property located in the Etzatlán region of Jalisco, Mexico.

The La Vencedora concession covers approximately 1,200 hectares, and the completed acquisition has provided AABB with 100% ownership of the mining concession. In conjunction with the closing, the Company completed its legal and technical due diligence on the mining concession, as well as all associated ownership and title documentation.

In accordance with the terms of the acquisition, 50% of the $5.5 million purchase price will be paid in cash immediately, with the remainder payable in installments. No AABB common shares will be issued as part of the acquisition. The structure of the deal enables AABB to acquire the property without any shareholder dilution and with financial flexibility to develop and produce the property.

Following the Company’s previously announced Letter of Intent, the completion of the acquisition will enable the Company to progress towards mine preparation and extraction with initial mineralized material targeted for processing at the AABB Etzatlán gold and silver processing facility in Q4 2026. The La Vencedora mine is located approximately 18 kilometers from the AABB Etzatlán processing facility, thus enabling the extracted mineralized material to be transported directly to the Company’s existing processing facility.

Historically, the Company has obtained information about gold grades ranging from approximately 9 grams per ton (g/t) to 12 g/t and silver grades ranging from approximately 350 g/t to 400 g/t. These historical grades have been incorporated into the current mine plan and technical evaluations and do not constitute an estimate of the current mineral resource or reserves. La Vencedora is not an undeveloped exploration property. The mine contains approximately 1.3 kilometers of underground development on multiple levels and access points, and thus provides existing infrastructure to enable the Company to proceed with its initial mining program.

The existing underground development of the property is expected to help in reducing the initial development costs, compared with a new greenfield underground operation. Consequently, the Company will be able to focus its efforts on mine rehabilitation and production. Based on the current internal mine plan and technical evaluation, AABB expects to produce approximately 150 to 200 tons per day of mineralized underground material from the La Vencedora mine into the Etzatlán processing facility. This estimate is subject to mine development, grade continuity, equipment availability, extraction and processing performance.

The La Vencedora material will help the Company increase the Etzatlán production feed with another source of higher-grade material. Actual feed rate to the processing facility will be based on the production schedule, feed characteristics and processing performance. The underground hard-rock material is also expected to provide a relatively consistent flotation feed material to complement the Company’s existing surface and stockpile feed material. Management believes that this should improve the flexibility of the Etzatlán facility in blending the feed material and decrease certain difficulties in processing it.

Etzatlán processing facility utilizes extensive flotation system for processing mineralized rocks, and the characteristics of the underground material from La Vencedora are well-matched with the processing facilities. With the acquisition completed, AABB’s mining and technical teams will be working on mine preparation, rehabilitation, sequencing of initial extraction zones, equipment and personnel deployment, logistics and transportation planning and preparation of the material transportation and processing at the Etzatlán facility.

The Company targets the start of the extraction activities during Q4 2026, followed by delivering and processing of initial La Vencedora material at the Etzatlán processing facility. “The completion of the La Vencedora acquisition significantly improves our Etzatlán mining district,” said Chris Torres, AABB President and CEO. “We now own 1,200 hectares containing 1.3 kilometers of underground development at only 18 kilometers from our processing facility. Based on our current internal mine plan, we expect La Vencedora to provide approximately 150 to 200 tons per day of underground material to the Etzatlán processing plant.”

Torres added, “The structure of the deal is also beneficial for our shareholders, as 50% of the purchase price will be paid in cash immediately, the remainder payable in installments, and no AABB common shares will be issued. Our immediate focus is now on mine preparation and rehabilitation and the start of the La Vencedora production in Q4.”

The Company expects to provide additional updates as the development proceeds, including the initiation of the extraction program, production schedule, deliveries of mineralized material, processing volumes and the commencement of production from the La Vencedora material at the Etzatlán processing facility. AABB continues seeking opportunities to increase its precious metals production and properties portfolio in Mexico, particularly those most suitable to leverage the Company’s established processing facilities in Etzatlán.

About Asia Broadband

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production of precious metals and the accumulation of physical gold and silver holdings. The Company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate the expansion of precious metals property holdings and production in Mexico. The Company’s industry and business integration in Mexico and its asset diversification are unique strengths of AABB that differentiate it from other companies and creates distinctive value for shareholders. Additionally, the Company has a digital assets business segment with its AABBG and AABBS mine-to-token gold and silver-backed cryptocurrencies within its own proprietary GoldAxis Wallet and the unique Golden Baboons Mining Club and Shorts Rascal Club Non-Fungible Token (NFT) collections. AABB expects its token to become a world-wide standard of exchange that is stable, secured and trusted with gold backing, while having the added benefit of demand based price appreciation. These are unique and outstanding qualities relative to other cryptocurrencies and digital asset developers.

Contact the Company at:

General Email:	ir@asiabroadbandinc.com
Token Support:	support@aabbgmine2token.com
Company Websites:	www.asiabroadbandinc.com
	www.aabbgmine2token.com
	www.goldenbaboons.com
Phone:	702-744-4785

Forward-Looking Statements are contained in this press release within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the Asia Broadband Inc.’s (the “Company”) expected current beliefs about the Company’s business, which are subject to uncertainty and change. The operations and results of the Company could materially differ from what is expressed or implied by the statements made above when industry, regulatory, market and competitive circumstances change. Further information about these risks can be found in the annual and quarterly disclosures the Company has published on the OTC Markets website. The Company is under no obligation to update or alter its forward-looking statements as future circumstances, events and information may change.

Source: Asia Broadband Inc.

Exclusive collaboration debuts RMCF’s first-ever Miso Caramel, with only 250 available per participating store

DURANGO, Colo., Sept. 16, 2026 (GLOBE NEWSWIRE) — Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company” or “RMCF”), America’s Chocolatier® since 1981, today announced an exclusive limited-edition collaboration with Miraculous Corp’s Miraculous: Tales of Ladybug & Cat Noir, bringing the globally recognized entertainment franchise to select Rocky Mountain Chocolate Factory locations with a new limited-edition caramel apple.

Available September 15 through October 31, 2026, while supplies last, the Miraculous® Miso Caramel Apple features a Miso Caramel formulation developed exclusively for Miraculous®, marking the first time Rocky Mountain Chocolate Factory has offered the flavor in its stores. Only 250 Miraculous® Miso Caramel Apples will be available at each participating Rocky Mountain Chocolate Factory location, presented in exclusive limited-edition Miraculous® packaging.

A New Take on an RMCF Icon
The Miraculous® Miso Caramel Apple features a crisp apple dipped in Rocky Mountain Chocolate Factory’s new Miso Caramel. One half is finished with crunchy salted pretzel pieces, while the other is left smooth to showcase the Miso Caramel itself. The half-and-half design takes inspiration from Marinette’s transformation into Miraculous Ladybug, representing the progression from the everyday to the extraordinary. The combination brings together sweet, salty, and savory flavors in a distinctive interpretation of one of Rocky Mountain Chocolate Factory’s most recognizable products. The launch also taps into a growing sweet-and-savory flavor trend. Yelp’s January 2026 Trend Tracker reported that searches for “miso caramel” increased 107% year-over-year.

“We see collaborations like Miraculous® as an exciting way to introduce Rocky Mountain Chocolate Factory to new audiences while creating something unexpected for guests who already know and love us,” said David Denker, Chief Operating Officer of Rocky Mountain Chocolate Factory. “We wanted this Miraculous® collaboration to feel truly special, not simply like another seasonal product. Our team created a completely new flavor, bringing together sweet, salty and savory flavors in a way our guests have never experienced at RMCF. Even the design of the apple tells part of the story. From the flavor and texture to the limited-edition packaging and in-store experience, we wanted every element to feel intentional, fun to discover, and connected to the world of Miraculous®.”

Ashley Depp, Miraculous Corp.’s Senior Vice President of Marketing & Franchise, added, “Miraculous® has always celebrated the idea that heroes can be found in everyday life, and that even an ordinary moment can become something extraordinary. This collaboration with Rocky Mountain Chocolate Factory brings that spirit to life, giving families and fans a chance to share a treat, discover something new, and create their own Miraculous moment together.”

Innovation Meets Experiential Retail
For Rocky Mountain Chocolate Factory, the collaboration reflects a broader focus on developing new partnerships that create excitement and in-store experiences that invite new audiences and give existing fans another reason to visit. The Miraculous® activation combines product innovation and storytelling with the sights, smells, tastes and live candy-making theater that have defined Rocky Mountain Chocolate Factory for more than four decades. The franchise is also a global digital powerhouse, with 53 million subscribers and 55 billion lifetime views across more than 50 official YouTube channels. On TikTok, the brand boasts more than 1 billion views and 7 million followers.

Guests can follow Rocky Mountain Chocolate Factory and Miraculous social channels for product reveals, participating locations, in-store content and additional updates throughout the collaboration.

About Rocky Mountain Chocolate Factory, Inc.
Rocky Mountain Chocolate Factory, Inc. is a leading franchisor, manufacturer and retailer of premium chocolates and other confectionery products. As America’s Chocolatier^® since 1981, the Company produces an extensive assortment of premium chocolates, gourmet caramel apples and other handcrafted confections. Headquartered in Durango, Colorado, Rocky Mountain Chocolate Factory is ranked among Entrepreneur’s Franchise 500^® for 2026. Together with its franchisees and licensees, the Company operates approximately 250 Rocky Mountain Chocolate Factory locations across the United States and internationally. The Company’s common stock is listed on the Nasdaq Global Market under the symbol “RMCF.”

About Miraculous Corp
Miraculous Corp is the groundbreaking joint venture between Mediawan and ZAG established in 2024 to unite all facets of the globally acclaimed Miraculous® franchise. Headquartered in the United States, and with a creative studio based in Paris, Miraculous Corp oversees the franchise’s creative vision and commercial strategy to expand the Miraculous universe and its global footprint, ushering in a new era of iconic characters and captivating narratives.

Driven by a mission to inspire future heroes to change the world, Miraculous Corp creates stories that empower and engage kids and family audiences everywhere. The company’s dynamic portfolio includes the flagship property Miraculous: Tales of Ladybug & Cat Noir. Season seven is in production for a late 2026 launch, and a theatrical feature is in development, produced by John Cohen (Despicable Me). The portfolio also includes the Miraculous® Chibi (52 x 3′), as well as Miraculous® Stellar Force (26 x 22′), the first original spin-off series in the Miraculous® universe.

Mediawan is Europe’s premier independent production powerhouse led by Pierre-Antoine Capton, known for acclaimed titles such as Miraculous, Adolescence, Call My Agent, 3 Body Problem, HIP, The Count of Monte Cristo, and Rhythm and Flow. ZAG, the innovative independent animation studio led by Jeremy Zag, has gained global recognition for creating the ZAG HEROEZ label, including Miraculous and Ghostforce.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future operational initiatives, strategic priorities, product innovation, franchise growth, and shareholder value creation. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties are described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

Investor Contact
Sean Mansouri, CFA
Elevate IR
(720) 330-2829
RMCF@elevate-ir.com

Media Contact
Raymond Barrett
Director of Marketing
(305) 801-5641
rbarrett@rmcf.net

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b1c4c2b-7f85-40a9-93cc-a13b6c6a7186

New York, New York, Sept. 16, 2026 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) (“Antelope Enterprise”, “AEHL” or the “Company”), which provides livestreaming ecommerce services, business management and information systems consulting services in China, today announced the closing of its previously announced offering of 8.00% convertible promissory notes in an aggregate principal amount of $6.0 million (the “Note”) to an accredited investor.

The Company received net proceeds from the offering of the Note of approximately $5.965 million, after deducting estimated offering expenses.

The Note bears interest at a rate of 8.00% per annum, which accrues from September 10, 2026 until the Note is paid in full, and is payable in cash. The Note has no fixed maturity date and the Note in full or in any portion is convertible into the Company’s Class A ordinary shares, no par value per share, at the option of the holder at any time on or after September 10, 2026. The conversion price is equal to 80% of the lowest daily volume-weighted average price (VWAP) of the ordinary shares on the Nasdaq Capital Market during the three trading days ending on and including the applicable conversion date.

Conversions of the Note are subject to both (i) the Nasdaq 19.99% issuance cap under Nasdaq Listing Rule 5635 and (ii) a strict beneficial ownership limitation, meaning the holder will not have the right to convert any portion of the Note if, immediately following such conversion, the holder and its affiliates would beneficially own in excess of 9.99% of the Company’s issued and outstanding ordinary shares. Additionally, the ordinary shares issuable upon conversion of the Note are subject to a Conversion Shares Registration Cap of 12,000,000 shares.

The Notes were offered pursuant to a “shelf” registration statement on Form F-3 (File No. 333-295047), that was previously filed by the Company and became effective under the rules of the Securities and Exchange Commission (the “SEC”) on May 5, 2026. A prospectus supplement relating to the Offering was filed with the SEC and was available on the website of the SEC at www.sec.gov. Before investing in the Offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC, which provide more information about the Company and the Offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Any unregistered conversion shares issued in excess of the registration cap will constitute “restricted securities” under the Securities Act of 1933, as amended, and may not be offered, sold, or otherwise transferred absent an effective registration statement or an available exemption from registration.

About Antelope Enterprise Holdings Limited

Antelope Enterprise Holdings Limited (“Antelope Enterprise”, “AEHL” or the “Company”) engages holds a 51% ownership position in Hainan Kylin Cloud Services Technology Co. Ltd (“Kylin Cloud”), which operates a livestreaming e-commerce business in China. For more information, please visit our website at https://aehltd.com.

Safe Harbor Statement

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, without limitation, future Bitcoin market performance and developments in the Bitcoin industry, our ability to regain customers lost resulting in a decline in our revenues, the continued stable macroeconomic environment in the PRC, the consumer and technology sectors continuing to exhibit sound long-term fundamentals, our ability to continue as a going concern, our ability to raise capital to meet our capital needs, and our ability to continue to grow our business management, information system consulting, and online social commerce and live streaming business. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 6-K for the year ended March 31, 2026 and otherwise in our SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

Contact Information:
Antelope Enterprise Holdings Limited
Xiaoying Song, Chief Financial Officer
info@aehltd.com

WFS Investor Relations Inc.
Email: services@wfsir.com
+1 628 283 9214

Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment

• James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026
• Presentation is expected to address development and clinical translation of ONP-002, including the intranasal delivery platform, Phase IIa trial design, and anticipated path to U.S. clinical development
• Forum convenes leading pharmaceutical scientists, device developers, and regulators focused on nasal drug delivery

SARASOTA, Fla., Sept. 16, 2026 (GLOBE NEWSWIRE) — Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that James P. Kelly, MD, Chief Medical Officer, is scheduled to present at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026. The event is being held September 16–17, 2026, at Liberty House in Jersey City, New Jersey.

Dr. Kelly is scheduled to present during Session 4: Successful Case Studies, beginning at 9:40 AM ET. His presentation is expected to address the development and clinical translation of ONP-002, Oragenics’ first-in-class intranasal neurosteroid candidate for the treatment of concussion — a condition with no currently approved pharmacological treatments.

The presentation is expected to highlight the scientific rationale underlying ONP-002’s proposed mechanism of action, including its potential ability to reduce neuroinflammation, oxidative stress, and cerebral edema through the proposed simultaneous activation of multiple neuroprotective pathways. Dr. Kelly is expected to discuss the design of the Company’s proprietary breath-powered intranasal delivery device, the ongoing Phase IIa feasibility trial in Australia, and the clinical design framework for anticipated U.S. development.

ONP-002 is manufactured as a powder and delivered via a lightweight intranasal device engineered to direct the drug to the superior nasal roof for direct olfactory nerve, brain delivery, minimizing systemic exposure. A Phase IIa feasibility trial is currently enrolling at three sites in Australia, and the Company is advancing its Investigational New Drug (IND) application, with submission anticipated in Q4 2026.

Dr. Kelly stated, “The IPAC-RS Nasal Innovation Forum is an ideal venue to share the science underpinning our intranasal platform with the formulation, device, and regulatory community. Concussion represents a significant unmet need, and we are excited to present our progress toward potentially bringing the first pharmacological treatment for this condition to patients.”

The IPAC-RS Nasal Innovation Forum is an annual pharmaceutical industry forum dedicated to nasal drug delivery, convening scientists, device innovators, and regulatory experts to discuss formulation science, device technology, manufacturing best practices, and regulatory strategy.

About ONP-002

ONP-002 is a first-in-class intranasal neurosteroid being investigated for the treatment of mTBI (concussion). There are currently no FDA-approved pharmacological treatments for mTBI. ONP-002 is designed to reduce neuroinflammation, oxidative stress, and cerebral edema through gene amplification of multiple neuroprotective pathways simultaneously. The compound is spray-dry manufactured into a nanoparticle powder and delivered via a proprietary breath-powered intranasal device designed to maximize olfactory deposition and direct brain delivery while minimizing systemic exposure. Phase I single and multiple ascending dose safety trials have been completed with a favorable safety and tolerability profile. A Phase IIa feasibility trial is currently enrolling in Australia.

About Oragenics

Oragenics is a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology. The Company’s lead candidate, ONP-002, is being developed as a potential first-in-class treatment for mTBI (concussion). Oragenics is advancing ONP-002 through Phase IIa clinical trials in Australia, with U.S. Phase IIb trials planned to follow pending IND submission. The Company’s intranasal delivery platform has potential applications across a range of acute and chronic neurological conditions. For more information, visit www.oragenics.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements concerning the Company’s expectations, plans, business outlook, or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance, or other matters are forward-looking statements. These statements include, but are not limited to, statements regarding the expected timing and outcomes of the Company’s Phase IIa and planned Phase IIb clinical trials, the Company’s regulatory strategy and engagement with the FDA, the anticipated timing of the Company’s IND submission, the potential applications of Oragenics’ intranasal delivery platform, and the Company’s ability to advance its clinical programs with available capital. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to the clinical development process, patient enrollment and trial execution, regulatory approval processes, the Company’s ability to secure adequate funding for operations, and those risks set forth in Oragenics’ most recent Forms 10-K, 10-Q, and other SEC filings available through EDGAR at www.sec.gov. Oragenics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release, except as may be required by law.

CONTACTS
Investor Relations
irth Communications
1-866-976-4784
IR@oragenics.com

Media Relations
irth Communications
1-866-976-4784
media@irthcommunications.com

Source: Oragenics

Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies

THE WOODLANDS, TX, Sept. 16, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the appointment of Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel of Medtronic plc (Medtronic) as a Board Member for Autonomix.

Ms. Kalter brings more than four decades of experience across the medical device and healthcare industries, including extensive senior-level experience at Medtronic, one of the world’s largest and most diversified medical technology companies. During her tenure at Medtronic, she played a key role in regulatory, clinical and strategic initiatives spanning multiple business units and oversaw due diligence and integration activities associated with more than 27 acquisitions.

Her Medtronic experience includes supporting some of the company’s most significant and innovative technologies, including the Symplicity Spyral^™ Renal Denervation system, Evolut^™ TAVR platform, Micra^™ Transcatheter Pacing System, and PulseSelect^™ Pulsed Field Ablation system. Her experience also includes involvement with the acquisition and integration of technologies that contributed to Medtronic’s expansion of its renal denervation platforms and electrophysiology.

“Sandy brings an extraordinary level of MedTech experience to Autonomix, particularly from her time at Medtronic, where she was at the intersection of regulatory strategy, clinical development, technology evaluation and corporate transactions,” said Walter Klemp, Chairman of the Board of Autonomix. “Her firsthand understanding of how a global medical device leader evaluates emerging technologies, navigates regulatory pathways and approaches strategic partnerships and acquisitions is exceptionally valuable to Autonomix as we advance our technology and expand our relationships across the industry.”

As a Board Member, Ms. Kalter will provide strategic guidance to Autonomix’s Board and management team as the Company advances its proprietary technologies and evaluates opportunities to expand its technology across additional therapeutic applications. Her experience is also expected to support the Company’s strategic discussions with potential industry partners and other stakeholders as Autonomix continues to develop its platform.

“I am excited to join Autonomix as a Board Member at an important stage in the Company’s development,” said Sandra Cohen Kalter. “Having spent much of my career at Medtronic helping guide innovative technologies through complex regulatory, clinical and strategic processes, I understand the importance of combining strong technology with a thoughtful development and commercialization strategy. Autonomix has developed a differentiated approach to nerve sensing and targeted therapy, leveraging advanced technology to potentially revolutionize how clinicians detect, interpret and treat nerve-related conditions. I believe Autonomix is well positioned to advance this technology toward clinical development and unlock its broader potential across the medical device landscape. I look forward to working with the Board and management team as the Company moves this important technology forward.”

Extensive Medtronic Experience

During her 20 years at Medtronic, Ms. Kalter served in senior legal regulatory leadership roles, including Vice President and Chief Regulatory Counsel, advising Medtronic business units on FDA strategy, clinical and legal regulatory matters, quality systems, product development and commercialization.

Her Medtronic experience includes:

• More than 27 acquisitions: Oversaw due diligence and integration activities for more than 27 acquisitions, including technologies that expanded Medtronic’s capabilities in renal denervation, electrophysiology and other areas of medical technology.
• Category-defining technologies: Regulatory and strategic involvement with major Medtronic platforms including Symplicity Spyral^™ Renal Denervation, Evolut^™ TAVR, Micra^™ Transcatheter Pacing System and PulseSelect^™ PFA.
• FDA and legal regulatory leadership: Built and managed an in-house FDA legal team supporting Medtronic’s business units and helping guide legal regulatory strategies for innovative medical technologies.
• Strategic technology evaluation: Extensive experience evaluating emerging medical technologies and navigating the regulatory, clinical and strategic considerations involved in bringing innovative devices into major medical device portfolios.

Prior to joining Medtronic, Ms. Kalter spent 13 years as FDA/Healthcare Counsel at King & Spalding LLP, where she advised clients on complex FDA regulatory matters, including regulatory filings and FDA advisory panel proceedings.

“Sandy’s experience is particularly relevant to where Autonomix is headed,” commented Brad Hauser, Chief Executive Officer of Autonomix. “We are developing technology at the intersection of sensing, neuromodulation and minimally invasive intervention, and her experience with major platforms in renal denervation and electrophysiology gives her a unique perspective on the opportunity in front of us. We are thrilled to have her strategic insight as we work to advance Autonomix toward clinical development and ultimately position the Company for broader industry partnerships.”

Ms. Kalter received a Juris Doctor degree from The George Washington University National Law Center and a Bachelor of Science in Journalism from Northwestern University.

About Autonomix Medical, Inc. 

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements 

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the potential effectiveness and clinical benefits of Autonomix’s nerve-targeted treatments for pancreatic cancer pain and other conditions, the versatility and scalability of the Company’s platform technology, the potential for future clinical applications across multiple organ systems, the strength and scope of the Company’s intellectual property portfolio, and the potential for the Company’s patented technologies to support patient selection, procedural guidance and post-treatment monitoring across multiple neuromodulation applications.

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact 

JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

Attachment

• Autonomix Medical, Inc.

The recognition highlights the company’s commitment to earning trust across customers, employees, and investors

KEY POINTS

• ASUS named for the third time by Newsweek as one of the World’s Most Trustworthy Companies, reflecting strong stakeholder confidence
• The ranking aligns with the company’s commitment to a people-first culture built on a design-thinking approach and transparent supply chain practices
• ASUS validated for its company values, management, and long-term potential driven by its Ubiquitous AI. Incredible Possibilities. strategy

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — ASUS today announced its inclusion among Newsweek’s World’s Most Trustworthy Companies in 2026, for the third consecutive year. This recognition is awarded to companies that have gained the trust of consumers, investors, and employees. It also underscores the company’s commitment to reliability and excellence in the Technology Hardware industry.

The Newsweek ranking acknowledges companies that have earned customer confidence in their products, services, advertising, communication, and complaint handling; investor confidence in company values, management, and long-term potential; and employee satisfaction with fair treatment, compensation, workplace appeal, and career development. This aligns with the ASUS commitment to a people-first culture built on a design-thinking approach and transparent supply chain practices.

“We are honored that ASUS has once again been recognized by Newsweek as one of the World’s Most Trustworthy Companies,” said S.Y. Hsu, ASUS Co-CEO. “This recognition reinforces the importance of earning confidence and creating long-term value for customers, employees, and investors through our Ubiquitous AI. Incredible Possibilities strategy as we deliver comprehensive AI solutions across Infrastructure, Physical AI, AI PCs and devices.”

“We are proud to receive this recognition from Newsweek, which underscores our commitment to responsible innovation and sustainable growth,” said Samson Hu, ASUS Co-CEO. “The company’s approach combines user-focused innovation with responsible business practices, including efforts to support a more sustainable future by designing products that balance high performance with environmental responsibility, using governance and initiatives such as our AI x ESG Platform.”

Building trust through Ubiquitous AI. Incredible Possibilities

ASUS is committed to fostering trust through its Ubiquitous AI. Incredible Possibilities. strategy, aiming to make AI accessible to everyone, everywhere. This involves delivering comprehensive AI solutions that span public and private clouds, general and personal intelligence, and seamless cloud-edge collaboration.

ASUS achieves this by designing high-performance products with environmental responsibility in mind. The company builds lasting stakeholder trust by combining innovation, AI leadership, and strong employee engagement. Bolstered by robust R&D and strategic global partnerships, ASUS maintains its leadership in AI PCs, gaming, and servers, while also providing transformative solutions across smart healthcare, cities, retail, and manufacturing, highlighting its broad global impact and earned confidence.

About Newsweek World’s Most Trustworthy Companies

The World’s Most Trustworthy Companies 2026, compiled by Newsweek in its third edition, recognizes 1,000 companies across 23 industries and 20 countries that have earned the confidence of customers, investors, and employees. The ranking evaluates companies from multiple perspectives — including customers, investors, and employees — taking into account factors such as product quality, corporate values, management competency, employee treatment, and career development opportunities. This recognition highlights companies that consistently demonstrate reliability, transparency, and strong governance.

NOTES TO EDITORS

ASUS Homepage: https://www.asus.com/ca-en/

ASUS AI PCs: https://www.asus.com/ca-en/content/asus-ai-pc/

ASUS Sustainability: https://esg.asus.com/

ASUS Pressroom: http://press.asus.com

ASUS Canada Facebook: https://www.facebook.com/asuscanada/

ASUS Canada Instagram: https://www.instagram.com/asus_ca

ASUS Canada YouTube: https://ca.asus.click/youtube

ASUS Global X (Twitter): https://www.x.com/asus

About ASUS

ASUS (2357.TW) is an innovative technology leader delivering the world’s most comprehensive AI solutions across Infrastructure, Physical AI, AI PC/Devices, and Engineering the AI Advantage. Guided by its “Ubiquitous AI. Incredible Possibilities.” strategy, ASUS is bringing enterprise-to-edge AI to life. The ASUS portfolio also includes the ROG and ProArt sub-brands, which serve gamers and creators worldwide.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/72c1ab82-6cf6-4146-af03-3283d5061dbf

CONTACT: PRESS CONTACTS

Redoine Taoussi

Senior Public Relations Manager

Redoine_Taoussi@asus.com

Sessions will highlight Orchestra BioMed’s collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyond

NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that its investigational Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) will be featured in two sessions at HRX Live 2026 — the Heart Rhythm Society’s annual innovation-focused meeting taking place September 18-20, 2026, in Atlanta, Georgia.

A sponsored roundtable will focus on Orchestra BioMed’s strategic collaboration with Medtronic to accelerate the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a cardiac pacemaker. A second panel will explore the expanding role of permanent pacing beyond bradycardia, including AVIM Therapy as an emerging cardiac pacing-based approach to treat uncontrolled hypertension and hypertensive heart disease.

Roundtable on AVIM Therapy & Medtronic Collaboration

Accelerating AVIM Therapy for Hypertensive Heart Disease: The Medtronic / Orchestra BioMed Innovation Partnership (Saturday, September 19, 2026, 9:40-10:25 a.m. ET)

• Moderator: Vivek Reddy, MD, Director of Cardiac Arrhythmia Services, The Mount Sinai Fuster Heart Hospital; Director of Electrophysiology, Mount Sinai Health System
• Panelists: Robert C. Kowal, MD, PhD, Vice President and General Manager of Cardiac Pacing Therapies, Medtronic Electrophysiology Therapies; Andrea Russo, MD, Academic Chief, Division of Cardiology, and Director of Cardiac Electrophysiology and Arrhythmia Services, Cooper University Hospital; Charles Love, MD, Professor of Medicine and Director of Cardiac Rhythm Device Services, Johns Hopkins Hospital; and David Hochman, Chairman, Chief Executive Officer and Founder of Orchestra BioMed

The panel will explore AVIM Therapy’s mechanism of action and potential as a cardiac pacing-based treatment for hypertension, the most common comorbidity among pacemaker-indicated patients. Panelists will review clinical evidence showing immediate, substantial and sustained reductions in systolic blood pressure, as well as improvements in hemodynamics and cardiac function. They will also provide an update on the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) and examine the Orchestra BioMed and Medtronic collaboration as a differentiated model for accelerating medical device innovation. Dr. Reddy serves as Executive Chairman of the BACKBEAT Trial Steering Committee, Dr. Russo serves as Co-Principal Investigator of the trial, and Dr. Love serves as a member of the Steering Committee.

Dr. Reddy commented, “AVIM Therapy exemplifies the kind of innovation HRX was created to showcase. It builds on the long-established pacemaker platform, expanding cardiac pacing into hypertension therapy, a critically important area of clinical need, the leading risk factor for death worldwide, and the most common comorbidity in pacemaker patients. The BACKBEAT Trial is nearing enrollment completion, and the collaboration between Orchestra BioMed and Medtronic offers a compelling model for accelerating the development of a potentially transformative therapy for the large population of patients living with uncontrolled hypertension.”

Panel Session Featuring AVIM Therapy

Permanent Pacing but not for Bradycardia (Friday, September 18, 2026, 4:45-5:30 p.m. ET)

• Moderator: Robert C. Kowal, MD, PhD, Vice President and General Manager of Cardiac Pacing Therapies, Medtronic Electrophysiology Therapies
• Panelists: Prof. Karl-Heinz Kuck, MD, University Heart Center Lübeck; Andrea Russo, MD, Cooper University Hospital; Margaret Infeld, MD, Tufts Medical Center; Daniel Friedman, MD, Duke University School of Medicine; and Daniel Lustgarten, MD, PhD, University of Vermont Medical Center

This panel will explore the expanding role of permanent cardiac pacing beyond the treatment of bradycardia. AVIM Therapy will be among several emerging pacing-based applications featured in the discussion.

David Hochman, Chairman, Chief Executive Officer and Founder of Orchestra BioMed, added, “The inclusion of AVIM Therapy in two HRX Live 2026 sessions reflects growing recognition within the electrophysiology community that AVIM Therapy can play a significant role in expanding the therapeutic value of cardiac pacing. We look forward to engaging with the clinicians, innovators and industry leaders shaping the future of cardiovascular care. These discussions will focus on AVIM Therapy’s potential to address the significant unmet need among patients with uncontrolled hypertension and hypertensive heart disease.”

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates – Atrioventricular Interval Modulation (AVIM) Therapy and Virtue^® Sirolimus AngioInfusion™ Balloon (Virtue SAB) – are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities.

AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk.

Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease.

For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

About AVIM Therapy

AVIM Therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM Therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM Therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal trial is evaluating the safety and efficacy of AVIM Therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM Therapy has been granted two Breakthrough Device Designations by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the initiation, enrollment, timing, implementation and design of the Company’s ongoing pivotal trials, realizing the clinical and commercial value of AVIM Therapy and Virtue SAB, the potential safety and efficacy of the Company’s product candidates, and the ability of the Company’s partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s commercial product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 12, 2026 as updated by any risk factors disclosed under the heading “Item 1A. Risk Factors” in Part II of the Company’s subsequently filed quarterly reports on Form 10-Q.

Investor Contact:

Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com

Media Contact:

Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com